The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy

DOI10.1093/biostatistics/kxm028zbMath1143.62078WikidataQ80808145 ScholiaQ80808145MaRDI QIDQ3526154

Yanqing Sun, Peter B. Gilbert, Ian W. McKeague

Publication date: 25 September 2008

Published in: Biostatistics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1093/biostatistics/kxm028

zbMATH Keywords

survival analysis; proportional hazards; competing risks; mark variable; genetic data

Mathematics Subject Classification ID

62G10: Nonparametric hypothesis testing

62G20: Asymptotic properties of nonparametric inference

62P10: Applications of statistics to biology and medical sciences; meta analysis

92C50: Medical applications (general)

62N03: Testing in survival analysis and censored data

Related Items

The Kaplan-Meier Integral in the Presence of Covariates: A Review, Hypotheses Tests of Strain-specific Vaccine Efficacy Adjusted for Covariate Effects, Nonparametric Two‐Sample Tests of the Marginal Mark Distribution with Censored Marks, Mark‐Specific Hazard Ratio Model with Multivariate Continuous Marks: An Application to Vaccine Efficacy, Mark-specific hazard ratio model with missing multivariate marks, Nonparametric analysis of bivariate gap time with competing risks, Simultaneous confidence bands for Cox regression from semiparametric random censorship, Model assisted Cox regression, Proportional hazards model for competing risks data with missing cause of failure, Proportional hazards models with continuous marks, Goodness-of-fit test of the stratified mark-specific proportional hazards model with continuous mark, Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy, Analysis of the time-varying Cox model for the cause-specific hazard functions with missing causes, Mark-specific additive hazards regression with continuous marks, Estimation of Stratified Mark-Specific Proportional Hazards Models with Missing Marks, Incorporating founder virus information in vaccine field trials